<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, but its efficacy in diffuse large cell (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), transformed (TL), and grade 3 follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FLG3) is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>In this phase II trial, 45 patients with relapsed or refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (n=32), TL (n=9), or FLG3 (n=4) who had received 1-4 prior lines of treatment were given 20â€‰mg oral lenalidomide on days 1-21 of each 28-day cycle and intravenous rituximab (375 mg/m(2)) weekly during cycle 1.  </plain></SENT>
<SENT sid="2" pm="."><plain>Grade 3/4 hematological toxicities included <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (53%), <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> (40%), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (33%), <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (27%), and <z:hpo ids='HP_0001903'>anemia</z:hpo> (18%), with a median follow-up time of 29.1 months (range, 14.7-52.0 months) </plain></SENT>
<SENT sid="3" pm="."><plain>OR rate was 33%; median response duration was 10.2 months </plain></SENT>
<SENT sid="4" pm="."><plain>Median PFS and OS were 3.7 and 10.7 months </plain></SENT>
<SENT sid="5" pm="."><plain>Nine of 15 responding patients (3 PR, 6 CR) proceeded with stem cell transplantation (SCT) and were censored at the time of transplant </plain></SENT>
<SENT sid="6" pm="."><plain>When data were analyzed without censoring, median PFS remained 3.7 months and response duration increased to 30.9 months </plain></SENT>
<SENT sid="7" pm="."><plain>Rituximab plus oral lenalidomide is well-tolerated and effective for patients with relapsed/refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and TL </plain></SENT>
<SENT sid="8" pm="."><plain>SCT after lenalidomide-rituximab is associated with prolonged response duration </plain></SENT>
<SENT sid="9" pm="."><plain>This study is registered at www.clinicaltrials.gov as NCT00294632.<z:hpo ids='HP_0001909'>Leukemia</z:hpo> accepted article preview online, 2 April 2013; doi:10.1038/leu.2013.95 </plain></SENT>
</text></document>